Lilly/BI biosimilar Lantus approved in Europe

Sanofi's blockbuster long-lasting insulin, Lantus, faces market erosion in Europe following the approval there of a biosimilar version from Lilly and Boehringer Ingelheim. Their insulin glargine product, with the provisional brand name Abasria, is the first insulin treatment to be approved through the European Medicines Agency's biosimilar pathway.

Sanofi's blockbuster long-lasting insulin, Lantus, faces market erosion in Europe following the approval there of a biosimilar version from Lilly and Boehringer Ingelheim. Their insulin glargine product, with the provisional brand name Abasria, is the first insulin treatment to be approved through the European Medicines Agency's biosimilar pathway.

The product was recommended for approval by the EMA's Committee for Medicinal Products for Human Use (CHMP) in June, so...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip